Andrea van Elsas

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

Andrea van Elsas, Arthur A. Hurwitz, James P. Allison · The Journal of Experimental Medicine · 1999 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

Roger P.M. Sutmuller, Leonie M. van Duivenvoorde, Andrea van Elsas et al. · The Journal of Experimental Medicine · 2001 · 1K citations · Full text

Life Sciences, Immunology, Oncology +17

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

Burkhard Jansen, Hermine Schlagbauer‐Wadl, Bob D. Brown et al. · Nature Medicine · 1998 · 487 citations

Medicine, Oncology, Pharmacology +13

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Kelsey E. Sivick, Anthony L. Desbien, Laura Hix Glickman et al. · Cell Reports · 2018 · 438 citations · Full text

Life Sciences, Immunology, Oncology +17

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

Yu‐Tzu Tai, Chirag Acharya, Gang An et al. · Blood · 2016 · 355 citations

Medicine, Hematology, Oncology +14